CN1264552C - Preparation of preventing osteoporosis and delaying senility and its preparation process - Google Patents
Preparation of preventing osteoporosis and delaying senility and its preparation process Download PDFInfo
- Publication number
- CN1264552C CN1264552C CN 200310117191 CN200310117191A CN1264552C CN 1264552 C CN1264552 C CN 1264552C CN 200310117191 CN200310117191 CN 200310117191 CN 200310117191 A CN200310117191 A CN 200310117191A CN 1264552 C CN1264552 C CN 1264552C
- Authority
- CN
- China
- Prior art keywords
- preparation
- group
- compound preparation
- calcium carbonate
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a preparation of preventing osteoporosis and delaying senility and a preparation process thereof. The preparation is mainly prepared from rehmannia root, poria cocos, Chinese yam, soybean isoflavone, calcium carbonate and vitamin D. The preparation process of the preparation of the present invention comprises the following steps: crushing the soybean isoflavone, the calcium carbonate and the vitamin D; respectively decocting the rehmannia root, the poria cocos and the Chinese yam by water so as to obtain water decocting solutions, and then merging the water decocting solutions; filtering, deslagging and concentrating so as to obtain thick paste, drying, and then crushing dried paste for reserving. The present invention has the advantages of simple and easy preparation technology, low cost, outstanding curative effect, specific effect, such as bone density increment, osteoporosis prevention, senility delay, etc., security and no toxic side effect.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation and preparation method thereof, particularly relate to a kind of bone density improving, compound preparation of prevention of osteoporosis and slow down aging and preparation method thereof.
Background technology
A kind of osteopathia that osteoporosis system is caused by multiple reason, along with population life-time dilatation and social senilization, osteoporosis is deeply hurt increasing people.Statistics shows that existing this type of patient of China has eight or nine thousand ten thousand people, not only influences patient's quality of life, has brought huge economic heavy burden also for country and patient family.The medicine that is used to prevent and treat at present mainly contains estrogens and calcium preparation.But because the relation that estrogen replacement therapy and breast carcinoma take place remains in dispute, use estrogen to prevent and treat osteoporosis for the women and need weigh the advantages and disadvantages, double cautious.And the absorption of calcium preparation is the problem that needs solution at present.Preventing and treating osteoporosis is a permanent process, because administration time is long, it is first that selected medicine especially should be looked safety.
Summary of the invention
The object of the invention is to provide a kind of bone density improving, the compound preparation of prevention of osteoporosis and slow down aging and the preparation method of this compound preparation.
The present invention seeks to be achieved through the following technical solutions:
Preparation of the present invention is made up of following raw material:
Radix Rehmanniae 100-300 weight portion, Poria 100-300 weight portion, Rhizoma Dioscoreae 100-300 weight portion, soybean isoflavone 2-6 weight portion, calcium carbonate 10-26 weight portion, vitamin D 3500-6500IU.
The above-mentioned raw materials optimum ratio is:
Radix Rehmanniae 150-250 weight portion, Poria 150-250 weight portion, Rhizoma Dioscoreae 150-250 weight portion, soybean isoflavone 2.5-4.5 weight portion, calcium carbonate 14.5-18.5 weight portion, vitamin D 4000-5000IU.
Above-mentioned raw materials medicine proportioning is:
Radix Rehmanniae 100-300g, Poria 100-300g, Rhizoma Dioscoreae 100-300g, soybean isoflavone 2-6g, calcium carbonate 10-26g, vitamin D3 000-7000IU.
Preparation of the present invention can add adjuvant and make clinical acceptable forms such as tablet, capsule, oral liquid, granule; Described adjuvant comprises solvent, disintegrating agent, correctives, antiseptic, coloring agent, binding agent, lubricant, substrate etc.
The concrete preparation technology of the present invention is as follows:
Take by weighing soybean isoflavone, calcium carbonate, the vitamin D of formula ratio, pulverize, cross 100 mesh sieves, it is standby to get fine powder; Take by weighing the Radix Rehmanniae, Poria, the Rhizoma Dioscoreae of formula ratio, add 7-9,6-8,5-7 times water successively, decoct three times, from the timing of when boiling, be respectively 1.5-2.5 hour, 0.5-1.5 hour, 0.5-1.5 hour, collecting decoction filters, slagging-off; Filtrate decompression is concentrated into the thick paste of d＞1.2, puts 50～60 ℃ of cold drying in the vacuum desiccator, is dried to the dried cream of moisture＜3%r, and dried cream powder is broken, and medicated powder is crossed the 80-100 mesh sieve, and is standby; With above-mentioned standby medicated powder mix homogeneously; With microwave sterilizating, its sterilising conditions is: 3～5 kilowatts of power, and frequency 2450 megahertzes, the time is 10-20 second, promptly.
Get the formula ratio soybean isoflavone, calcium carbonate, 100 mesh sieves are pulverized, crossed to vitamin D, and it is standby to get fine powder; Get the formula ratio Radix Rehmanniae, Poria, Rhizoma Dioscoreae adds 8,7,6 times of water successively, decocts three times, and meter is 2 hours, 1 hour, 1 hour during respectively from boiling, and collecting decoction filters, slagging-off; Filtrate decompression is concentrated into the thick paste of d＞1.2, puts 50～60 ℃ of cold drying in the vacuum desiccator, is dried to the dried cream of moisture＜3%r, and dried cream powder is broken, and medicated powder is crossed 80 mesh sieves, and is standby; With above-mentioned standby medicated powder mix homogeneously; With microwave sterilizating, its sterilising conditions is: 3～5 kilowatts of power, and frequency 2450 megahertzes, the time is 15 seconds; Add adjuvant and make the dosage form of clinical acceptance, promptly.
The composition that preparation technology's of the present invention outstanding progress and remarkable result are this compound preparation is common being easy to get, processing technology is simple and easy, with low cost, determined curative effect, Pharmacodynamic test of active extract result shows: have clear and definite bone density improving, effect such as prevention of osteoporosis and slow down aging, and safety non-toxic.These pharmacological actions are confirmed by following pharmacodynamic experiment example.
Experimental example 1: the effect of this compound preparation bone density improving
Material and method
Laboratory animal: the ablactation WISTAR male rat (secondary) about body weight 80 grams, available from Institute of Experimental Animals, Chinese Academy of Medical Sciences breeding farm, approval number: SCXK11-00-0006 number.After adapting to a week, be divided into five groups at random by body weight, 10 every group, ad lib, drink deionized water.
Animal grouping and dosage are selected: the GUSHUKANG capsule test group (be equivalent to respectively human body recommended amounts 5,10,30 times) of normal feedstuff group, calcium carbonate control group and 0.48g/kgBW, 0.96g/kgBW, three dosage of 2.88g/kgBW, this GUSHUKANG capsule are established in test
The 1st group: normal feedstuff group, every hectogram feedstuff calcic 150mg;
The 2nd group: normal feedstuff adds calcium carbonate control group, every hectogram feedstuff calcic 340mg;
The 3rd group: normal feedstuff adds GUSHUKANG Capsules group (0.48g/kg), is equivalent to every hectogram feedstuff calcic 182mg;
The 4th group: normal feedstuff adds GUSHUKANG Capsules group (0.96g/kg), is equivalent to every hectogram feedstuff calcic 214mg;
The 5th group: normal feedstuff adds GUSHUKANG Capsules group (2.88g/kg), is equivalent to every hectogram feedstuff calcic 340mg;
Contain in every 1000g normal feedstuff:
Casein 10g analysis for soybean powder 15g Semen Tritici aestivi flour 54g
Semen Maydis oil or Oleum Arachidis hypogaeae semen 4g cellulose 2g mixed vitamin 2g
Choline chloride 1g d1-methionine 0.2g starch 11g
Salt-mixture 2.6g
Experimental result:
1, the GUSHUKANG capsule is to the influence of rat body weight, height
Table 1 is respectively organized the body weight change before and after the rat experiment
| Group (Ca:mg/100g feedstuff) | Number of animals | Body weight | P 1 | P 2 | |
| Before the experiment | After the experiment | ||||
| Normal feedstuff group (150) calcium carbonate control group (340) 0.48 GUSHUKANG capsules (182) 0.96 GUSHUKANG capsules (214) 2.88 GUSHUKANG capsules (340) | 10 10 10 10 10 | 79.1±1.7 79.0±1.5 79.5±1.5 79.8±3.9 79.4±1.7 | 364.4±3.8 423.3±4.2 ** 365.4±4.0 394.8±3.9 ** 429.1±3.2 **### | - 0.000 0.685 0.000 0.000 | - - - - 0.003 |
P
1: compare * * with the normal feedstuff group: P＜0.01
P
2: compare ##:P＜0.01 with calcium carbonate control group
By table 1 as seen, the feed rat bone is dredged recovering capsule after 12 weeks, GUSHUKANG capsule 0.96,2.88g/kg dosage group rat body weight are apparently higher than normal feedstuff group (P＜0.01), and 2.88g/kg dosage group and calcium carbonate control group comparison rat body weight obviously increase (P＜0.05).
The height that table 2 is respectively organized before and after the rat experiment changes
| Group (Ca:mg/100g feedstuff) | Number of animals | Height (cm) | P 1 | P 2 | |
| Before the experiment | After the experiment | ||||
| Normal feedstuff group (150) calcium carbonate control group (340) 0.48 GUSHUKANG capsules (182) 0.96 GUSHUKANG capsules (214) 2.88 GUSHUKANG capsules (340) | 10 10 10 10 10 | 16.76±0.12 16.76±0.12 16.79±0.15 16.76±0.14 16.78±0.10 | 24.40±0.20 26.56±0.35 ** 24.69±0.15 ** 26.35±0.23 ** 27.06±0.19 ** | - 0.000 0.003 0.000 0.000 | - - - - 0.001 |
P
1: compare * * with the normal feedstuff group: P＜0.01
P
2: compare ##:P＜0.01 with calcium carbonate control group
By table 2 as seen, the feed rat bone is dredged recovering capsule after 12 weeks, and each dosage group rat height of GUSHUKANG capsule is apparently higher than normal feedstuff group (P＜0.01); 2.88g/kg dosage group and the apparent in view increase of calcium carbonate control group rat height (P＜0.01).
2, the GUSHUKANG capsule is to the influence of femur length and femur weight
Table 3 rat femur length
| Group (Ca:mg/100g feedstuff) | Number of animals (only) | Femur length (cm) | P 1 | P 2 |
| Normal feedstuff group (150) calcium carbonate control group (340) 0.48 GUSHUKANG capsules (182) 0.96 GUSHUKANG capsules (214) 2.88 GUSHUKANG capsules (340) | 10 10 10 10 10 | 3.39±0.02 3.35±0.03 ** 3.41±0.05 3.51±0.01 ** 3.58±0.02 **## | - 0.000 0.042 0.000 0.000 | - - - - 0.002 |
P
1: compare * * with the normal feedstuff group: P＜0.01
P
2: compare ##:P＜0.01 with calcium carbonate control group
By table 3 as seen, the feed rat bone is dredged recovering capsule after 12 weeks, the rat femur length of GUSHUKANG capsule 0.96,2.88g/kg dosage group is significantly higher than normal feedstuff group (P＜0.01), and 2.88g/kg dosage group and calcium carbonate control group comparison rat femur length obviously increase (P＜0.01).
Table 4 rat femur weight
| Group (Ca:mg/100g feedstuff) | Number of animals (only) | Femur weight (g) | P 1 | P 2 |
| Normal feedstuff group (150) calcium carbonate control group (340) 0.48 GUSHUKANG capsules (182) 0.96 GUSHUKANG capsules (214) 2.88 GUSHUKANG capsules (340) | 10 10 10 10 10 | 1.00±0.02 1.14±0.02 ** 1.05±0.01 ** 1.08±0.02 ** 1.16±0.02 ** | - 0.000 0.000 0.000 0.000 | - - - - 0.066 |
P
1: compare * * with the normal feedstuff group: P＜0.01
P
2: compare ##:P＜0.01 with calcium carbonate control group
By table 4 as seen, the feed rat bone is dredged recovering capsule after 12 weeks, the rat femur weight of each dosage group of GUSHUKANG capsule is significantly higher than normal feedstuff group (P＜0.01), and 2.88g/kg dosage group and calcium carbonate control group comparison rat femur weight do not have significant difference (P＞0.05).
3, the GUSHUKANG capsule is to the influence of rat bone density
Table 5 is respectively organized rat femur metaphysis bone density relatively
| Group (Ca:mg/100g feedstuff) | Number of animals (only) | Femur metaphysis bone density (g/cm 2) | P 1 | P 2 |
| Normal feedstuff group (150) calcium carbonate control group (340) 0.48 GUSHUKANG capsules (182) 0.96 GUSHUKANG capsules (214) 2.88 GUSHUKANG capsules (340) | 10 10 10 10 10 | 0.288±0.002 0.300±0.002 ** 0.293±0.002 ** 0.300±0.002 ** 0.305±0.002 **## | - 0.000 0.000 0.000 0.000 | - - - - 0.000 |
P
1: compare * * with the normal feedstuff group: P＜0.01
P
2: compare ##:P＜0.01 with calcium carbonate control group
Table 6 is respectively organized rat femur mid point bone density relatively
| Group (Ca:mg/100g feedstuff) | Number of animals (only) | Femur mid point bone density (g/cm 2) | P 1 | P 2 |
| Normal feedstuff group (150) calcium carbonate control group (340) 0.48 GUSHUKANG capsules (182) 0.96 GUSHUKANG capsules (214) 2.88 GUSHUKANG capsules (340) | 10 10 10 10 10 | 0.273±0.004 0.290±0.004 ** 0.274±0.003 0.292±0.005 ** 0.300±0.004 **## | - 0.000 0.588 0.000 0.000 | - - - - 0.000 |
P
1: compare * * with the normal feedstuff group: P＜0.01
P
2: compare ##:P＜0.0 with calcium carbonate control group
By table 5,6 as seen, after 12 weeks of feed GUSHUKANG capsule, each dosage group rat femur metaphysis bone density of GUSHUKANG capsule is apparently higher than normal feedstuff group (P＜0.01), GUSHUKANG capsule 0.96,2.88g/kg dosage group femur mid point bone density are apparently higher than normal feedstuff group (P＜0.01), 2.88g/kg dosage group rat femur density is apparently higher than calcium carbonate control group, difference has significance (P＜0.01).
Experimental example 2: the research of compound preparation delaying senility function
Material and method
Grouping: rat experiment divides pure water matched group and basic, normal, high three dosage groups, and dosage is as follows:
Low dose group: 0.5g/kg is equivalent to recommend 5 times of day dosing.
In dosage group: 1.0g/kg, be equivalent to recommend 10 times of day dosing.
High dose group: 3.0g/kg is equivalent to recommend 30 times of day dosing.
The fruit bat experiment divides matched group and 0.033%, 0.070%, four dosage groups of 0.200% GUSHUKANG capsule.
Animal: the SD rat, male, at 20 monthly ages, body weight 320 ± 70 is latent, and animal quality certification 2001A046 is provided by medical experimental animal field, Guangdong Province.Pellet is provided by medical experimental animal field, Guangdong Province.
Copulation Oregon K Drosophila melanogaster is not provided by Shanghai Railway Univ's medical college.
Laboratory: cleaning level, the quality certification number: Guangdong searching 2001C047.Room temperature 22 ± 2 degree, humidity 65%-80%.
Instrument: the biochemical incubator of constant temperature, the MPF-4 of Hitachi type spectrofluorophotometer, 721 type spectrophotometers, the flat culture tube of 3X13CM.
Route of administration: rat experiment is tried thing by 1ml/100g filling stomach every day; The fruit bat experiment will be tried thing and according to dosage be added normal feedstuff, free diet.
Normal feedstuff: Semen Maydis powder 10%, brown sugar 13.5%, agar 0.09%, benzoic acid 0.30%, dried yeast powder 1%, water 73.85%.Transfer PH5.5.
Experimental result:
1, the GUSHUKANG capsule is to the influence of life span of drosophila melanogaster
Table 7 GUSHUKANG capsule is to the influence (fruit bat several 200) of male life span of drosophila melanogaster
| Group | Dosage | Body weight | Half death | Maximum life span | Average life |
| Dosage II high dose F value among the dosage I in the matched group low dosage | 0 0.033 0.070 0.200 0.600 | 705 721 702 716 713 | 43.0 50.0 45.0 43.0 43.0 | 58.8±2.1 60.8±1.5 ** 59.9±1.9 * 57.6±2.0 58.9±2.6 7.391(P＜0.01) | 43.5±9.5 46.9±10.3 43.8±11.1 42.8±9.8 41.8±10.8 7.409(P＜0.01) |
Annotate: * * represents to compare P＜0.01 with matched group, and * and matched group be P＜0.05 relatively
Table 8 GUSHUKANG capsule is to the influence (fruit bat several 200) of female life span of drosophila melanogaster
| Group | Dosage | Body weight | Half death | Maximum life span | Average life |
| Dosage II high dose F value among the dosage I in the matched group low dosage | 0 0.033 0.070 0.200 0.600 | 890 935 945 933 956 | 61.0 65.0 65.0 61.0 62.0 | 70.2±0.7 73.8±1.2 ** 74.5±1.1 ** 73.2±1.0 ** 71.5±2.4 31.60(P＜0.01) | 60.3±8.8 63.1±9.2 * 62.4±9.8 61.1±8.5 60.5±7.7 3.722(P＜0.05) |
Annotate: * * represents to compare P＜0.01 with matched group, and * and matched group be P＜0.05 relatively
Male: the maximum life span of experimental group, prolong than matched group, to learn by statistics and handle, 0.033% experimental group difference has highly significant meaning (P＜0.01), and 0.070% experimental group difference has significance meaning (P＜0.05); The average life of experimental group prolongs than matched group, learns by statistics and handles, and 0.033% experimental group difference has highly significant meaning (P＜0.01); 0.033%, the half death time of the male fruit bat of 0.070% experimental group prolongs 7 days and 2 days than matched group respectively.
Female: the maximum life span of experimental group prolongs than matched group, learns by statistics and handles, and 0.033%, 0.070%, 0.200% experimental group difference has highly significant meaning (P＜0.01); The average life of experimental group prolongs than matched group, and learning processing 0.033% experimental group difference by statistics has significance meaning (P＜0.05); 0.033%, the half death time of 0.070%, the 0.600% female fruit bat of experimental group prolongs 4 days, 4 days and 1 day than matched group respectively.
The result shows: the GUSHUKANG capsule has the life-saving effect to fruit bat.
2, the GUSHUKANG capsule is to the influence of laboratory animal serum lipid peroxidation catabolite malonaldehyde (MDA) content
Table 9 is dredged the influence of health capsule to laboratory animal MDA content
| Group | Dosage (g/kg) | Number of animals | MDA content (nmol/ml) |
| X±SD | |||
| Dosage group high dose group F value in the matched group low dose group | 0.00 0.50 1.00 3.00 | 12 13 13 13 | 4.60±1.13 3.78±1.29 * 3.55±0.48 * 3.51±0.85 ** 3.268(P＜0.05) |
Annotate: * * represents to compare P＜0.01 with matched group, and * and matched group be P＜0.05 relatively.
By table 9 as a result as can be known: high dose group lipid peroxide catabolite malonaldehyde (MDA) content reduces than matched group, learn by statistics and handle, difference has highly significant meaning (P＜0.01), low, middle dosage group lipid peroxide content of degradation products reduces than matched group, and learning processing difference by statistics has significance meaning (P＜0.05).
3 GUSHUKANG capsules are to the influence of laboratory animal serum sudismase (SOD) vigor
Table 10 is dredged the influence of health capsule to laboratory animal SOD vigor
| Group | Dosage (g/kg) | Number of animals | SOD vigor (NU1/ml) |
| X±SD | |||
| Dosage group high dose group F value in the matched group low dose group | 0.00 0.50 1.00 3.00 | 12 13 13 13 | 175.0±8.1 195.6±4.8 ** 194.6±7.6 ** 192.7±6.9 ** 23.65(P＜0.01) |
Annotate: * * represents to compare P＜0.01 with matched group.
By table 10 as a result as can be known: the SOD vigor of each dosage group increases than matched group, learns by statistics and handles, and difference all has highly significant meaning (P＜0.01).
Embodiment 1The capsular preparation method of compound preparation
Get soybean isoflavone 3.5g, calcium carbonate 16.5g, Vitamin D5. 000IU pulverizes, crosses 100 mesh sieves, and it is standby to get fine powder; Get Radix Rehmanniae 200g, Poria 200g, Rhizoma Dioscoreae 200g adds 8,7,6 times of water successively, decocts three times, and meter is 2 hours, 1 hour, 1 hour during respectively from boiling, and collecting decoction filters, slagging-off; Filtrate decompression is concentrated into the thick paste of d＞1.2, puts 50～60 ℃ of cold drying in the vacuum desiccator, is dried to the dried cream of moisture＜3%r, and dried cream powder is broken, and medicated powder is crossed 80 mesh sieves, and is standby; With above-mentioned standby medicated powder mix homogeneously; With microwave sterilizating, its sterilising conditions is: 3～5 kilowatts of power, and frequency 2450 megahertzes, the time is 10 seconds, and above-mentioned powder is filled in the 0# capsule, every 0.5 gram is made 200.Promptly.
Embodiment 2The preparation method of compound preparation tablet
Get soybean isoflavone 2.5g, calcium carbonate 14.5g, vitamin D3 750IU pulverizes, crosses 100 mesh sieves, and it is standby to get fine powder; Get Radix Rehmanniae 150g, Poria 150g, Rhizoma Dioscoreae 150g adds 8,7,6 times of water successively, decocts three times, and meter is 2 hours, 1 hour, 1 hour during respectively from boiling, and collecting decoction filters, slagging-off; Filtrate decompression is concentrated into the thick paste of d＞1.2, puts 50～60 ℃ of cold drying in the vacuum desiccator, is dried to the dried cream of moisture＜3%r, and dried cream powder is broken, and medicated powder is crossed 80 mesh sieves, and is standby; With above-mentioned standby medicated powder mix homogeneously; With microwave sterilizating, its sterilising conditions is: 3～5 kilowatts of power, frequency 2450 megahertzes, the time is 20 seconds, above-mentioned powder through the pelletizing machine granulate, tabletting, every heavy 0.5 the gram, make 200.Promptly.
Embodiment 3The application of compound preparation capsule in the osteoporotic medicine of treatment
Get Radix Rehmanniae 250g, Poria 250g, Rhizoma Dioscoreae 250g, soybean isoflavone 4.5g, calcium carbonate 18.5g, vitamin D 6250IU makes 330 of capsules, every 0.5 gram, sufferers of osteoporosis face is taken, and each 4, every day 3 times.
Claims (6)
1, a kind of bone density improving, the compound preparation of prevention of osteoporosis and slow down aging is characterized in that this compound preparation made by following raw material: Radix Rehmanniae 100-300g, Poria 100-300g, Rhizoma Dioscoreae 100-300g, soybean isoflavone 2-6g, calcium carbonate 10-26g, vitamin D3 000-7000IU.
2, compound preparation as claimed in claim 1 is characterized in that this compound preparation made by following proportioning raw materials: Radix Rehmanniae 150-250g, Poria 150-250g, Rhizoma Dioscoreae 150-250g, soybean isoflavone 2.5-4.5g, calcium carbonate 14.5-18.5g, vitamin D3 500-6500IU.
3, compound preparation as claimed in claim 1 or 2 is characterized in that this compound preparation adds adjuvant and makes tablet, capsule or granule.
4, the preparation method of compound preparation as claimed in claim 1 or 2 is characterized in that technology realizes this compound preparation by being prepared as follows: get soybean isoflavone, calcium carbonate, the vitamin D of formula ratio, pulverize, cross 100 mesh sieves, fine powder is standby; Take by weighing the Radix Rehmanniae, Poria, the Rhizoma Dioscoreae of formula ratio, add 7-9,6-8,5-7 times water successively, decoct three times, from when boiling meter 1.5-2.5 hour, 0.5-1.5 hour, 0.5-1.5 hour, collecting decoction filtered, slagging-off respectively; Filtrate decompression is concentrated into the thick paste of d＞1.2, puts 50～60 ℃ of cold drying in the vacuum desiccator, is dried to the dried cream of moisture＜3%r, and dried cream powder is broken, and medicated powder is crossed the 80-100 mesh sieve, and is standby; With above-mentioned standby medicated powder mix homogeneously; With microwave sterilizating, its sterilising conditions is: 3～5 kilowatts of power, and frequency 2450 megahertzes, the time is 10-20 second; Add adjuvant and make the dosage form of clinical acceptance, promptly.
5, the preparation method of compound preparation as claimed in claim 4 is characterized in that technology realizes this compound preparation by being prepared as follows: get the formula ratio soybean isoflavone, calcium carbonate, 100 mesh sieves are pulverized, crossed to vitamin D, fine powder is standby; Get the formula ratio Radix Rehmanniae, Poria, Rhizoma Dioscoreae adds 8,7,6 times of water successively, decocts three times, and meter is 2 hours, 1 hour, 1 hour during respectively from boiling, and collecting decoction filters, slagging-off; Filtrate decompression is concentrated into the thick paste of d＞1.2, puts 50～60 ℃ of cold drying in the vacuum desiccator, is dried to the dried cream of moisture＜3%r, and dried cream powder is broken, and medicated powder is crossed 80 mesh sieves, and is standby; With above-mentioned standby medicated powder mix homogeneously; With microwave sterilizating, its sterilising conditions is: 3～5 kilowatts of power, and frequency 2450 megahertzes, the time is 15 seconds; Add adjuvant and make the dosage form of clinical acceptance, promptly.
6, the application of compound preparation as claimed in claim 1 or 2 in the medicine of preparation treatment and prevention of osteoporosis, bone density improving or slow down aging.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310117191 CN1264552C (en) | 2003-12-05 | 2003-12-05 | Preparation of preventing osteoporosis and delaying senility and its preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310117191 CN1264552C (en) | 2003-12-05 | 2003-12-05 | Preparation of preventing osteoporosis and delaying senility and its preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1623592A CN1623592A (en) | 2005-06-08 |
| CN1264552C true CN1264552C (en) | 2006-07-19 |
Family
ID=34760925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310117191 Expired - Fee Related CN1264552C (en) | 2003-12-05 | 2003-12-05 | Preparation of preventing osteoporosis and delaying senility and its preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1264552C (en) |
-
2003
- 2003-12-05 CN CN 200310117191 patent/CN1264552C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1623592A (en) | 2005-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1084206C (en) | Cancer treating medicine and its preparation | |
| CN1903280A (en) | Yukangsan herb medicine powder for treating fish diseases | |
| CN1907358A (en) | Pharmaceutical composition for preventing and treating avian coccidiosis and its preparing method | |
| CN1875996A (en) | A composition having anti-oxygenation function | |
| CN1346600A (en) | Process for preparing antibiotic-free pollution-free feed of domestic animals and fawls and its product | |
| CN103006916A (en) | Pure traditional Chinese medicine recipe for curing various animal diarrhoeal diseases and preparation method of pure traditional Chinese medicine recipe | |
| CN101040924A (en) | Chinese traditional medicine for treating fowl coccidiosis and the preparing method thereof | |
| CN106173380A (en) | A kind of pig feed preventing and treating ascariasis | |
| CN107259226A (en) | A kind of eutrophy Chinese herbal medicine cray feed and preparation method thereof | |
| CN103272091A (en) | Traditional Chinese medicinal oral preparation for treating chicken coccidiosis and preparation method thereof | |
| CN105661031A (en) | High-protein chicken feed formula and preparation method of chicken feed | |
| CN1264552C (en) | Preparation of preventing osteoporosis and delaying senility and its preparation process | |
| CN1168488C (en) | Chinese medicinal preparation for treating pyretic stranguria | |
| CN1286501C (en) | Medicine composition for treating stomach disease, its preparation method and use | |
| CN1134238A (en) | Additive baishichuqinkang for farm animal feed and its producing method | |
| CN1233260C (en) | Chinese medicine fodder additives for increasing milk and fitting cow and preparing method | |
| CN1264543C (en) | Medicine for treating baby and child diarrhea and its preparation method | |
| CN109601880B (en) | Health food for increasing bone mineral density | |
| CN1150916C (en) | Fish medicine for preventing fish from raising nose above water | |
| CN1231255C (en) | Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method | |
| CN100345534C (en) | Yinzhi huang capsule, its preparation method and use | |
| CN1237994C (en) | Medicine composition for preparing canker and preparing method thereof | |
| CN1762386A (en) | Bone density-increasing and senility-postponing capsule formulation | |
| CN1233403C (en) | Medicine for preventing and treating infectious coryza | |
| CN1261156C (en) | Medicine for treating chronic gastroenteritis and colitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060719 Termination date: 20131205 |